Covid-19

Abstract

The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2) remains a serious issue for global health, given widespread infectivity and a high contagion rate. A tremendous amount of data has been generated since it was first identified in December 2019. It is vital to keep up with these data from across the world at a time of uncertainty and continuously evolving guidelines and clinical practice. This review provides an update on recent developments concerning epidemiology, clinical presentation, treatment options, and scientific advancements to combat the COVID-19 pandemic.

Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients

“…The most common symptoms are represented by fever, dry cough, muscle aches, “shortness of breath”, and headache, while symptoms such as rhinorrhea, sore throat, and those affecting the gastrointestinal system are rarer [ 4 ]. More severe complications include respiratory failure, neurological symptoms, acute kidney injury (AKI), shock, and death [ 5 ].…”

Genomic epidemiology of SARS-CoV-2 in the United Arab Emirates reveals novel virus mutation, patterns of co-infection and tissue specific host innate immune response

“…There were five large sub-clades including more than half of the collected samples (381 out of the 637 unique viral genomes, 59.81%) ( Figure 2A) , differentiated by eleven mutations that were common in the UAE viral population (allele frequency > 5%) and that were significantly less common among the worldwide viral population (P < 3.94e-82, Fisher exact test) ( Figure 2B, Table 1 ). The five sub-clades were (1) 19B.1 which consisted of 17.27% of the 637 UAE unique samples, harboring the G28878A, G29742A, G11230T and G28167A mutations; (2) 20B.1 which consisted of 8.48% of the samples, harboring the T7171C and C27002T mutations; (3) 20B.2 which consisted of 19.15% of the samples, harboring the T21775G and G5924A mutations; (4) 20B.3 which consisted of 8.95% of the samples, harboring the G23311T mutation and (5) 20B.4 which consisted of 5.97% of the samples, harboring the C7851T and the A24170G mutations.…”

“…Patients infected by SARS-CoV-2 can experience a number of serious respiratory illnesses and have in many cases died from complications related to the infection( 4 ). There are no specific therapeutics or fully validated vaccines available for its control to date( 5, 6 ). Dynamic transmission modelling considering seasonal variation, immunity and intervention suggests a high possibility of continuing waves of resurgence until the year 2025( 7 ).…”

Teleneurorehabilitation in the COVID-19 Era: What Are We Doing Now and What Will We Do Next?

“…Thus, the disease has had many impacts on people around the world including, among other issues, the need to stay at home, avoid public gatherings, wear masks and gloves. Notably, these issues are more difficult for persons with neurological disabilities who are the most vulnerable because of the altered mobility and cognitive dysfunction, the need for assistance for self-care, assistive devices, and supplies [ 1 , 2 ].…”

“…Dear Editor, COVID-19 is an acute respiratory illness caused by the SARS-COV2, whose transmission occurs via droplets or direct contact with contaminated objects (i.e., fomites). Thus, the first-line preventive strategies are to increase the social distances, and potentiate all general prevention measures regarding the common infective respiratory diseases [1].…”